Jennifer graduated in 2009 from the University of Bath with a First Class MChem honours degree in Chemistry for Drug Discovery with Industrial Training. She then completed a PhD in Organic Chemistry at the University of Bath, focusing on the asymmetric synthesis of highly substituted lactones for use in natural product synthesis. She joined HGF in May 2016.
Jennifer’s undergraduate degree provided her with a broad understanding of medicinal chemistry, including some aspects of biochemistry and pharmacology. She completed an industrial placement at AstraZeneca where she worked as a Synthetic Organic Chemist in the lead optimisation stage of drug discovery. Her PhD research involved the development of novel methodology for the asymmetric synthesis of building blocks for use in natural product synthesis. This work resulted in three publications and was presented at two international conferences.
After her PhD, Jennifer spent two years working in R&D for a specialist diabetes diagnostics company. This project focused on the design and synthesis of novel boronic acid fluorophore conjugates for use in an HbA1c assay.
Before joining HGF, Jennifer was the Industry Manager for the NIHR Diagnostic Evidence Cooperative based at Imperial College London. During this time, she was responsible for developing a portfolio of industry collaborative clinical studies for Point-of-Care in vitro diagnostic device evaluation.
Chemistry for Drug Discovery
Organic Synthetic Chemistry
Jennifer organised a firm-wide tutorial series for trainee patent attorneys who took the UK qualifying exams in 2018 and 2019. She also regularly attends IP Inclusive events.
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
HGF Partner Dr Susan Keston and Senior Patent Attorney Dr Sofie McPherson will be presenting a webinar ‘How to capitalise on the 5G healthcare revolution’ on 25th May. This session will explore how 5G …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.